Shawver LK, Slamon D, Ullrich A. Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002;1:117–23.

Article  PubMed  CAS  Google Scholar 

Radich JP, Deininger M, Abboud CN, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16:1108–35.

Article  Google Scholar 

•• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019;381:2315–26. The first clinical trial that led to the approval of asciminib for the treatment of chronic myeloid leukemia

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7.

Article  PubMed  CAS  Google Scholar 

Hantschel O, Nagar B, Guettler S, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 2003;112:845–57.

Article  PubMed  CAS  Google Scholar 

Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121:3818–24.

Article  PubMed  CAS  Google Scholar 

Hughes T, Boquimpani C, Takahashi N, et al. Durable treatment-free remission after stopping second line nilotinib in patients with chronic myeloid leukemia in chronic phase: ENESTOP 96-wk update. Haematologica. 2017;102:75.

Google Scholar 

Ross DM, Pagani IS, Shanmuganathan N, et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018;32:2572–9.

Article  PubMed  CAS  Google Scholar 

Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020;17:493–503.

Article  PubMed  Google Scholar 

•• Mahon F-X, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35. The first clinical trial to specifically evaluate the feasibility of tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients

Article  PubMed  CAS  Google Scholar 

Campbell VE, Copland M. Dasatinib for the treatment of chronic phase chronic myeloid leukemia. Clin Pract. 2013;10:415–25.

Article  CAS  Google Scholar 

Iurlo A, Galimberti S, Abruzzese E, et al. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol. 2018;97:95–100.

Article  PubMed  CAS  Google Scholar 

Emir H, Albrecht-Schgoer K, Huber K, et al. Nilotinib exerts direct pro-atherogenic and antiangiogenic effects on vascular endothelial cells: A potential explanation for drug-induced vasculopathy in CML. Blood. 2013;122:257.

Article  Google Scholar 

Hiwase DK, Carne L, Ross D, Grigg A, Hughes TP. Hypercholesterolaemia in imatinib intolerant/resistant CML-CP patients treated with nilotinib: A retrospective analysis. Blood. 2013;122:1503.

Article  Google Scholar 

Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol. 2012;30:3486–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404. The clinical trial that confirmed the efficacy and safety profile of ponatinib in the setting of Ph+ leukemias, including chronic myeloid leukemia

Article  PubMed  PubMed Central  CAS  Google Scholar 

Caocci G, Mulas O, Annunziata M, et al. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. Int J Cardiol. 2020;301:163–6.

Article  PubMed  Google Scholar 

Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J. Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care. Arterioscler Thromb Vasc Biol. 2020;40:301–8.

Article  PubMed  CAS  Google Scholar 

Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-Associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor–associated hypertension and vascular disease. Hypertension. 2017;71:e1-8.

PubMed  Google Scholar 

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM-L. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34:2851–7.

Article  PubMed  CAS  Google Scholar 

Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 2015;126:42–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29:1336–43.

Article  PubMed  CAS  Google Scholar 

Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nodzon L, Fadol A, Tinsley S. Cardiovascular adverse events and mitigation strategies for chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy. J Adv Pract Oncol. 2022;13:127–42.

Article  PubMed  PubMed Central  Google Scholar 

Sayegh N, Yirerong J, Agarwal N, et al. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Curr Cardiol Rep. 2023;25:269–80.

Article  PubMed  PubMed Central  Google Scholar 

Milojkovic D, Lyon AR, Mehta P, et al. Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management. Eur J Haematol. 2023;111:201–10.

Article  PubMed  CAS  Google Scholar 

Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020;191:171–93.

Article  PubMed  Google Scholar 

•• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. The latest version of the ELN recommendations for the diagnosis and treatment of chronic myeloid leukemia

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv261.

Article  PubMed  CAS  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361.

Article  PubMed  Google Scholar 

Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935–42.

PubMed  CAS  Google Scholar 

O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

Article  PubMed  CAS  Google Scholar 

Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

Article  PubMed  CAS  Google Scholar 

Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–61.

Article  PubMed  CAS  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Atallah E, Durand J-B, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib the